Ara
Toplam kayıt 6, listelenen: 1-6
Real-world data from the Turkish national chronic lymphocytic leukemia registry
(CIG Media Group, 2020)
Objective: We have previously established a nationwide registry to obtain real-world data to document the demographics and treatment outcomes of Turkish CLL patients. Patients or other participants: Patients who were ...
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
(Elsevier Science Inc, 2020)
Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ...
Artificial intelligence to assist better myeloma care, is it the time?
(Cıg Media Group, 2019)
Myeloma treatment made an enormous progress during the last decade. Armamentarium is grossly enlarging each year in the field of treatment. Parallel to the progress achieved to provide better care for myeloma patients, ...
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
(CIG Media Group, 2021)
Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ...
Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction
(CIG Media Group, 2022)
Introduction: There is a paucity of data regarding the best practice to institute iv Daratumumab (D) in morbid obese patients regarding the infusion rate and duration, optimal dosing, and ideal way to cope with the infusion ...
Successful use of frontline daratumumab lenalidomide and dexamethasone in transplant ineligible frail patients with moderate renal failure at the time of presentation
(CIG Media Group, 2022)
Introduction: Treatment of the elderly patients who have varying degrees of renal failure at the time of presentation, both due to the underlying plasma cell dyscrasia or the other comorbidities is a true challenge regarding ...